Literature DB >> 29235106

WNT signalling: mechanisms and therapeutic opportunities.

Gunnar Schulte1,2, Vitezslav Bryja2.   

Abstract

This themed section of the British Journal of Pharmacology stems from the EMBO Conference: Wnt Meeting 2016 held from the 14th to 16th September 2016 in Brno, Czech Republic. LINKED ARTICLES: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29235106      PMCID： PMC5727308          DOI： 10.1111/bph.14065

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  13 in total

Review 1.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

2.  WNT signalling: mechanisms and therapeutic opportunities.

Authors:  Gunnar Schulte; Vitezslav Bryja
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

Review 3.  WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.

Authors:  Else Driehuis; Hans Clevers
Journal:  Br J Pharmacol       Date:  2017-04-04       Impact factor: 8.739

Review 4.  Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy.

Authors:  Yung Lyou; Amber N Habowski; George T Chen; Marian L Waterman
Journal:  Br J Pharmacol       Date:  2017-08-24       Impact factor: 8.739

Review 5.  Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors.

Authors:  Dario Zimmerli; George Hausmann; Claudio Cantù; Konrad Basler
Journal:  Br J Pharmacol       Date:  2017-06-16       Impact factor: 8.739

Review 6.  Translation of WNT developmental programs into stem cell replacement strategies for the treatment of Parkinson's disease.

Authors:  Enrique M Toledo; Daniel Gyllborg; Ernest Arenas
Journal:  Br J Pharmacol       Date:  2017-07-09       Impact factor: 8.739

Review 7.  Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers.

Authors:  Dustin J Flanagan; Elizabeth Vincan; Toby J Phesse
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

Review 8.  Molecular regulation and pharmacological targeting of the β-catenin destruction complex.

Authors:  Eline C van Kappel; Madelon M Maurice
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 9.  Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.

Authors:  Laura Mariotti; Katie Pollock; Sebastian Guettler
Journal:  Br J Pharmacol       Date:  2017-11-05       Impact factor: 8.739

Review 10.  The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy.

Authors:  Akira Kikuchi; Katsumi Fumoto; Hirokazu Kimura
Journal:  Br J Pharmacol       Date:  2017-07-07       Impact factor: 8.739
View more
  4 in total

Review 1.  Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications.

Authors:  Ioannis Akoumianakis; Murray Polkinghorne; Charalambos Antoniades
Journal:  Nat Rev Cardiol       Date:  2022-06-13       Impact factor: 49.421

Review 2.  Activation of Wnt/Beta-Catenin Signaling Pathway as a Promising Therapeutic Candidate for Cerebral Ischemia/Reperfusion Injury.

Authors:  Zhizhun Mo; Zhongyi Zeng; Yuxiang Liu; Linsheng Zeng; Jiansong Fang; Yinzhong Ma
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

3.  WNT signalling: mechanisms and therapeutic opportunities.

Authors:  Gunnar Schulte; Vitezslav Bryja
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

4.  The GSK‑3β/β‑catenin signaling pathway is involved in HMGB1‑induced chondrocyte apoptosis and cartilage matrix degradation.

Authors:  Zhiyong Shu; Xiaogang Miao; Tainhua Tang; Peng Zhan; Langqing Zeng; Yuwen Jiang
Journal:  Int J Mol Med       Date:  2020-01-09       Impact factor: 4.101
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.